Tracers / [18F]AlF-RESCA-5F7
[18F]AlF-RESCA-5F7
Also written as [F-18]AlF-RESCA-5F7
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- HER2-targeting single-domain antibody (sdAb/nanobody) radiotracer labeled via Al18F-RESCA chelator strategy
- Target / mechanism
- Targets HER2 (human epidermal growth factor receptor 2) expression PMID 39027646
- Clinical application
- PET imaging probe for HER2 tumor imaging, potential companion diagnostic for iso-[211At]SGMAB-5F7 alpha therapy PMID 39027646
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | > 99% | — | 39027646 2024 Am J Nucl Med Mol Imaging |
Need this precursor?We can point you to suppliers for [18F]AlF-RESCA-5F7, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39027646. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.